Extract
We thank O. Moran-Mendoza and M. Khalil for their interest in our work. In their correspondence, they highlight differences between our findings and others, suggesting a re-analysis of our data after excluding studies that used bronchoalveolar lavage (BAL) lymphocyte % as part of the diagnostic criteria for fibrotic hypersensitivity pneumonitis (HP), in an effort to reduce incorporation bias. Given the absence of studies meeting these criteria, we find this suggestion unfeasible.
Abstract
No single value of BAL lymphocyte % in fibrotic hypersensitivity pneumonitis will be diagnostic for all, and it must be considered in the context of other clinical, radiological and histopathological features https://bit.ly/3qSwUDo
Footnotes
Conflict of interest: N. Adderley has nothing to disclose.
Conflict of interest: C.J. Humphreys has nothing to disclose.
Conflict of interest: H. Barnes has nothing to disclose.
Conflict of interest: Z.A. Premji has nothing to disclose.
Conflict of interest: K.A. Johannson reports personal fees for advisory board work and lectures, non-financial support and other from Boehringer Ingelheim, personal fees for lectures from Hoffman-La Roche Ltd, grants from The Chest Foundation, University of Calgary Cumming School of Medicine, UCB Biopharma SPRL and Pulmonary Fibrosis Society of Calgary, personal fees for consultancy from Blade Therapeutics and Theravance, personal fees for consultancy and non-financial support from Three Lakes Foundation, outside the submitted work.
- Received January 12, 2021.
- Accepted January 19, 2021.
- ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
